IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.

IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.

Global estimates of diabetes prevalence for 2013 and projections for 2035.

http://hub.hku.hk/bitstream/10722/235686/1/content.pdf

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants

Global estimates of undiagnosed diabetes in adults

The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults.

Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members.

BACKGROUND: COVID-19 mRNA vaccines were shown to be highly efficacious in preventing the disease in randomized controlled trials; nonetheless, evidence on the real-world effectiveness of this vaccine is limited. Study objective was to evaluate the effectiveness of BNT162b2 vaccine in preventing SARS-CoV-2 infection and COVID-19-related hospitalization and mortality. METHODS: This historical cohort study included members of a large health provider in Israel that were vaccinated with at least one dose of BNT162b2. The primary outcome was incidence rate of a SARS-CoV-2 infection confirmed with rt-PCR, between 7 to 27 days after second dose (protection-period), as compared to days 1 to 7 after the first dose, where no protection by the vaccine is assumed (reference-period). RESULTS: Data of 1,178,597 individuals vaccinated with BNT162b2 were analyzed (mean age 47.7 years [SD=18.1], 48.4% males) of whom 872,454 (74.0%) reached the protection period. Overall, 4514 infections occurred during the reference period compared to 728 during the protection period, yielding a weighted mean daily incidence of 54.8 per 100,000 (95%CI: 26.1-115.0 per 100,000) and 5.4 per 100,000 (95%CI: 3.5-8.4 per 100,000), respectively. The vaccine effectiveness in preventing infection was 90% (95%CI:79%- 95%) and 94% (95%CI:88%-97%) against COVID-19. Among immunosuppressed patients, vaccine effectiveness against infection was 71% (95%CI:37%-87%). The adjusted hazard ratios for hospitalization in those infected were 0.82 (95%CI:0.36-1.88), 0.45 (95%CI:0.23-0.90), and 0.56 (95%CI:0.36-0.89) in the age groups 16-44, 45-64 and 75 and above, respectively. CONCLUSIONS: The effectiveness of the BNT162b2 vaccine is comparable to the one reported in the phase III clinical trial.

/pdf/the-effectiveness-of-the-two-dose-bnt162b2-vaccine-analysis-e0iqkr3lyz.pdf

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data.

Problem The aim of this study was to investigate the prevalence of and the association between endometriosis, fibromyalgia, and autoimmune disease (AID) in a large population database and to describe healthcare resource utilization (HCRU) in affected women. Methods A retrospective cross-sectional study was performed using the computerized databases of Maccabi Healthcare Services (MHS), a 2.1-million-member healthcare plan in Israel. Age-sex-specific point prevalence rates of endometriosis and fibromyalgia were calculated for end of 2015. Socio-demographic characteristics, HCRU, co-morbidities, including AID and depression or anxiety were described according to endometriosis/fibromyalgia status and analyzed using ordinary logistic regression models. Results Among a total population of 781 571 adult women, 6647 were diagnosed with endometriosis (8.5 per 1000) and 25 425 with fibromyalgia (32 per 1000). A total of 401 women (0.5 per 1000) were diagnosed with both conditions. In 2015, the mean age of the women diagnosed with endometriosis and fibromyalgia was 42 and 55 years, respectively. Women with co-occurrence were characterized by increased HCRU and a high prevalence rate of AID compared to women with no diagnosis of endometriosis/fibromyalgia, with 6.2% diagnosed with inflammatory bowel disease (IBD) vs 1% in the comparison group. The prevalence of fibromyalgia in women with endometriosis was 6%. Adjusted ORs (95% CI) for fibromyalgia among endometriosis patients were 4.1 (2.02-8.36) for systemic lupus erythematosus (SLE), 3.1 (1.5-6.2) for Sjogren syndrome, 2.9 (1.87-4.7) for IBD, 2.1 (1.6-2.7) for dispensed antidepressants, and 1.7 (1.37-2.2) for diagnosed anxiety/depression. Conclusion Co-occurrence of endometriosis and fibromyalgia is associated with a high burden of AID, anxiety/depression, and HCRU.

Clara Weil

Papers

Global estimates of undiagnosed diabetes in adults

The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults.

Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members.

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data.

Evidence for an association between endometriosis, fibromyalgia, and autoimmune diseases